Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus o | IJNRD
Forxiga Full Prescribing Information, Dosage & Side Effects | MIMS Malaysia
Comparison of dapagliflozin plasma concentration time-profiles between... | Download Scientific Diagram
Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State - ScienceDirect
Dapagliflozin- a novel SGLT2 inhibitor | PPT
Role of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
JPM | Free Full-Text | Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans | Drug Metabolism & Disposition
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial | Drugs
Dapagliflozin - wikidoc
Geometric mean AUC and C max from PBPK model simulations compared with... | Download Scientific Diagram
Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, D | DDDT
Forxiga 10 mg Tablet - Uses, Dosage, Side Effects, Price, Composition | Practo
Dapagliflozin - wikidoc
Forxiga 5 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc)
Dapagliflozin - wikidoc
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus - Komoroski - 2009 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Dapagliflozin - wikidoc
Forxiga 10 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc)
SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment | Federal Practitioner
T2D Glycemic Control | Safety | FARXIGA® (dapagliflozin) 5 mg & 10 mg tablets | For HCPs
Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study | BMJ Open Diabetes
